NCT02389309: A Trial of Dasatinib (PDGFR and SRC Inhibitor), Temsirolimus and Cyclophosphamide in Patients With Advanced Solid Tumors

NCT02389309
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Tyrosine-Kinase Inhibitor, Serine-Threonine Kinase Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 12 Months to 20 Years (Child, Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: 
https://ClinicalTrials.gov/show/NCT02389309

Comments are closed.

Up ↑